Two FTC Officials Urge Staff To Change Course On CBD Enforcement Priorities, Impose 'Substantiation' Requirement Sparingly
This article was originally published on Hoban Law Group, and appears here with permission. As the hemp industry has come to understand by now, marketing hemp and/or CBD products with improper and unsubstantiated “disease” claims in the labeling violates a number of federal regulations. Since about 2015, the U.S. Food and Drug Administration (“FDA”) and/or U.S. Federal Trade Commission (“FTC”) has issued at least 70+ warning letters to businesses for marketing hemp products with illegal disease claims. Marketing CBD Products Of course, most of us know that marketing CBD products ...
Source: benzinga.com
